![]() |
|||||||
|
Fusion Protein:CPE-AMACR |
Fusion Gene and Fusion Protein Summary |
![]() |
Fusion partner gene information | Fusion gene name: CPE-AMACR | FusionPDB ID: 18945 | FusionGDB2.0 ID: 18945 | Hgene | Tgene | Gene symbol | CPE | AMACR | Gene ID | 1363 | 23600 |
Gene name | carboxypeptidase E | alpha-methylacyl-CoA racemase | |
Synonyms | CPH | AMACRD|CBAS4|P504S|RACE|RM | |
Cytomap | 4q32.3 | 5p13.2 | |
Type of gene | protein-coding | protein-coding | |
Description | carboxypeptidase Ecarboxypeptidase Hcobalt-stimulated chromaffin granule carboxypeptidaseenkephalin convertaseepididymis secretory sperm binding proteininsulin granule-associated carboxypeptidaseprohormone-processing carboxypeptidase | alpha-methylacyl-CoA racemase2-methylacyl-CoA racemase | |
Modification date | 20200313 | 20200313 | |
UniProtAcc | A4D0V7 Main function of 5'-partner protein: | Q9UHK6 Main function of 5'-partner protein: FUNCTION: Catalyzes the interconversion of (R)- and (S)-stereoisomers of alpha-methyl-branched-chain fatty acyl-CoA esters (PubMed:7649182, PubMed:10655068, PubMed:11060359). Acts only on coenzyme A thioesters, not on free fatty acids, and accepts as substrates a wide range of alpha-methylacyl-CoAs, including pristanoyl-CoA, trihydroxycoprostanoyl-CoA (an intermediate in bile acid synthesis), and arylpropionic acids like the anti-inflammatory drug ibuprofen (2-(4-isobutylphenyl)propionic acid) but neither 3-methyl-branched nor linear-chain acyl-CoAs (PubMed:7649182, PubMed:10655068, PubMed:11060359). {ECO:0000269|PubMed:10655068, ECO:0000269|PubMed:11060359, ECO:0000269|PubMed:7649182}. | |
Ensembl transtripts involved in fusion gene | ENST ids | ENST00000402744, | ENST00000382068, ENST00000382085, ENST00000426255, ENST00000441713, ENST00000502637, ENST00000512079, ENST00000514195, ENST00000335606, ENST00000382072, |
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0) | * DoF score | 8 X 5 X 5=200 | 28 X 3 X 4=336 |
# samples | 8 | 23 | |
** MAII score | log2(8/200*10)=-1.32192809488736 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(23/336*10)=-0.546827371834385 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Fusion gene context | PubMed: CPE [Title/Abstract] AND AMACR [Title/Abstract] AND fusion [Title/Abstract] | ||
Fusion neoantigen context | PubMed: CPE [Title/Abstract] AND AMACR [Title/Abstract] AND neoantigen [Title/Abstract] | ||
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | CPE(166300680)-AMACR(34006004), # samples:2 | ||
Anticipated loss of major functional domain due to fusion event. | CPE-AMACR seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. CPE-AMACR seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. CPE-AMACR seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. CPE-AMACR seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
![]() |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | CPE | GO:0016055 | Wnt signaling pathway | 22824791 |
Hgene | CPE | GO:0072657 | protein localization to membrane | 19166515 |
Tgene | AMACR | GO:0008206 | bile acid metabolic process | 10655068 |
![]() Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr4:166300680/chr5:34006004) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
![]() |
![]() |
![]() * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
![]() |
![]() * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
![]() |
Top |
Fusion Amino Acid Sequences |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000402744 | CPE | chr4 | 166300680 | + | ENST00000335606 | AMACR | chr5 | 34006004 | - | 4404 | 587 | 40 | 1488 | 482 |
ENST00000402744 | CPE | chr4 | 166300680 | + | ENST00000382072 | AMACR | chr5 | 34006004 | - | 3247 | 587 | 40 | 936 | 298 |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
ENST00000402744 | ENST00000335606 | CPE | chr4 | 166300680 | + | AMACR | chr5 | 34006004 | - | 0.000347235 | 0.99965274 |
ENST00000402744 | ENST00000382072 | CPE | chr4 | 166300680 | + | AMACR | chr5 | 34006004 | - | 0.095712654 | 0.90428734 |
![]() |
Get the fusion protein sequences from here. |
Fusion protein sequence information is available in the fasta format. >FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP |
Top |
Fusion Protein Breakpoint Sequences for CPE-AMACR |
![]() |
Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Length(fusion protein) | BP in fusion protein | Peptide |
CPE | chr4 | 166300680 | AMACR | chr5 | 34006004 | 587 | 182 | VIELSDNPGVHEPGVMEKLQLGPEIL |
Top |
Potential FusionNeoAntigen Information of CPE-AMACR in HLA I |
![]() |
CPE-AMACR_166300680_34006004.msa |
![]() * We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5) |
Fusion gene | Hchr | Hbp | Tgene | Tchr | Tbp | HLA I | FusionNeoAntigen peptide | Binding score | Immunogenic score | Neoantigen start (at BP 13) | Neoantigen end (at BP 13) |
CPE-AMACR | chr4 | 166300680 | chr5 | 34006004 | 587 | HLA-B47:01 | HEPGVMEKL | 0.9017 | 0.6458 | 10 | 19 |
CPE-AMACR | chr4 | 166300680 | chr5 | 34006004 | 587 | HLA-B18:01 | HEPGVMEKL | 0.8409 | 0.9694 | 10 | 19 |
CPE-AMACR | chr4 | 166300680 | chr5 | 34006004 | 587 | HLA-B39:13 | HEPGVMEKL | 0.613 | 0.9623 | 10 | 19 |
CPE-AMACR | chr4 | 166300680 | chr5 | 34006004 | 587 | HLA-A30:08 | GVHEPGVMEK | 0.9937 | 0.735 | 8 | 18 |
CPE-AMACR | chr4 | 166300680 | chr5 | 34006004 | 587 | HLA-B39:01 | VHEPGVMEKL | 0.9933 | 0.9184 | 9 | 19 |
CPE-AMACR | chr4 | 166300680 | chr5 | 34006004 | 587 | HLA-B38:01 | VHEPGVMEKL | 0.982 | 0.9659 | 9 | 19 |
CPE-AMACR | chr4 | 166300680 | chr5 | 34006004 | 587 | HLA-B38:02 | VHEPGVMEKL | 0.9815 | 0.9698 | 9 | 19 |
CPE-AMACR | chr4 | 166300680 | chr5 | 34006004 | 587 | HLA-B15:10 | VHEPGVMEKL | 0.9753 | 0.8288 | 9 | 19 |
CPE-AMACR | chr4 | 166300680 | chr5 | 34006004 | 587 | HLA-B15:37 | VHEPGVMEKL | 0.8987 | 0.8369 | 9 | 19 |
CPE-AMACR | chr4 | 166300680 | chr5 | 34006004 | 587 | HLA-B39:09 | HEPGVMEKL | 0.6821 | 0.643 | 10 | 19 |
CPE-AMACR | chr4 | 166300680 | chr5 | 34006004 | 587 | HLA-B39:08 | HEPGVMEKL | 0.6497 | 0.8304 | 10 | 19 |
CPE-AMACR | chr4 | 166300680 | chr5 | 34006004 | 587 | HLA-B39:09 | VHEPGVMEKL | 0.9928 | 0.6123 | 9 | 19 |
CPE-AMACR | chr4 | 166300680 | chr5 | 34006004 | 587 | HLA-B39:05 | VHEPGVMEKL | 0.9835 | 0.9167 | 9 | 19 |
CPE-AMACR | chr4 | 166300680 | chr5 | 34006004 | 587 | HLA-B40:04 | HEPGVMEKL | 0.9976 | 0.7217 | 10 | 19 |
CPE-AMACR | chr4 | 166300680 | chr5 | 34006004 | 587 | HLA-B18:05 | HEPGVMEKL | 0.8409 | 0.9694 | 10 | 19 |
CPE-AMACR | chr4 | 166300680 | chr5 | 34006004 | 587 | HLA-B18:08 | HEPGVMEKL | 0.8386 | 0.9391 | 10 | 19 |
CPE-AMACR | chr4 | 166300680 | chr5 | 34006004 | 587 | HLA-B18:06 | HEPGVMEKL | 0.7974 | 0.9756 | 10 | 19 |
CPE-AMACR | chr4 | 166300680 | chr5 | 34006004 | 587 | HLA-B18:03 | HEPGVMEKL | 0.7505 | 0.9672 | 10 | 19 |
CPE-AMACR | chr4 | 166300680 | chr5 | 34006004 | 587 | HLA-B18:11 | HEPGVMEKL | 0.7116 | 0.9524 | 10 | 19 |
CPE-AMACR | chr4 | 166300680 | chr5 | 34006004 | 587 | HLA-B41:03 | HEPGVMEKL | 0.6409 | 0.5741 | 10 | 19 |
CPE-AMACR | chr4 | 166300680 | chr5 | 34006004 | 587 | HLA-B39:31 | HEPGVMEKL | 0.6401 | 0.9617 | 10 | 19 |
CPE-AMACR | chr4 | 166300680 | chr5 | 34006004 | 587 | HLA-B39:02 | HEPGVMEKL | 0.6067 | 0.9612 | 10 | 19 |
CPE-AMACR | chr4 | 166300680 | chr5 | 34006004 | 587 | HLA-B59:01 | NPGVHEPGV | 0.4714 | 0.591 | 6 | 15 |
CPE-AMACR | chr4 | 166300680 | chr5 | 34006004 | 587 | HLA-B39:31 | VHEPGVMEKL | 0.9932 | 0.9242 | 9 | 19 |
CPE-AMACR | chr4 | 166300680 | chr5 | 34006004 | 587 | HLA-A30:01 | GVHEPGVMEK | 0.9916 | 0.842 | 8 | 18 |
CPE-AMACR | chr4 | 166300680 | chr5 | 34006004 | 587 | HLA-B38:05 | VHEPGVMEKL | 0.982 | 0.9659 | 9 | 19 |
CPE-AMACR | chr4 | 166300680 | chr5 | 34006004 | 587 | HLA-B15:09 | VHEPGVMEKL | 0.9257 | 0.6427 | 9 | 19 |
CPE-AMACR | chr4 | 166300680 | chr5 | 34006004 | 587 | HLA-B39:11 | VHEPGVMEKL | 0.8858 | 0.7631 | 9 | 19 |
Top |
Potential FusionNeoAntigen Information of CPE-AMACR in HLA II |
![]() |
![]() * We used NetMHCIIpan v4.1 (%rank<0.5). |
Fusion gene | Hchr | Hbp | Tgene | Tchr | Tbp | HLA II | FusionNeoAntigen peptide | Neoantigen start (at BP 13) | Neoantigen end (at BP 13) |
Top |
Fusion breakpoint peptide structures of CPE-AMACR |
![]() * The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA. |
File name | BPseq | Hgene | Tgene | Hchr | Hbp | Tchr | Tbp | AAlen |
6311 | NPGVHEPGVMEKLQ | CPE | AMACR | chr4 | 166300680 | chr5 | 34006004 | 587 |
Top |
Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of CPE-AMACR |
![]() * We used Glide to predict the interaction between HLAs and neoantigens. |
HLA allele | PDB ID | File name | BPseq | Docking score | Glide score |
HLA-B14:02 | 3BVN | 6311 | NPGVHEPGVMEKLQ | -8.85616 | -8.96956 |
HLA-B14:02 | 3BVN | 6311 | NPGVHEPGVMEKLQ | -5.66423 | -6.69953 |
HLA-B52:01 | 3W39 | 6311 | NPGVHEPGVMEKLQ | -6.49489 | -6.60829 |
HLA-B52:01 | 3W39 | 6311 | NPGVHEPGVMEKLQ | -3.99785 | -5.03315 |
HLA-A11:01 | 4UQ2 | 6311 | NPGVHEPGVMEKLQ | -4.90759 | -5.94289 |
HLA-A24:02 | 5HGA | 6311 | NPGVHEPGVMEKLQ | -7.27887 | -7.39227 |
HLA-A24:02 | 5HGA | 6311 | NPGVHEPGVMEKLQ | -7.11524 | -8.15054 |
HLA-B27:05 | 6PYJ | 6311 | NPGVHEPGVMEKLQ | -6.11615 | -6.22955 |
HLA-B27:05 | 6PYJ | 6311 | NPGVHEPGVMEKLQ | -4.78818 | -5.82348 |
HLA-B44:05 | 3DX8 | 6311 | NPGVHEPGVMEKLQ | -7.22602 | -7.33942 |
HLA-B44:05 | 3DX8 | 6311 | NPGVHEPGVMEKLQ | -4.86671 | -5.90201 |
Top |
Vaccine Design for the FusionNeoAntigens of CPE-AMACR |
![]() |
Fusion gene | Hchr | Hbp | Tchr | Tbp | Start in +/-13AA | End in +/-13AA | FusionNeoAntigen peptide sequence | FusionNeoAntigen RNA sequence |
CPE-AMACR | chr4 | 166300680 | chr5 | 34006004 | 10 | 19 | HEPGVMEKL | ATGAGCCTGGTGTCATGGAGAAACTCC |
CPE-AMACR | chr4 | 166300680 | chr5 | 34006004 | 6 | 15 | NPGVHEPGV | ACCCTGGCGTCCATGAGCCTGGTGTCA |
CPE-AMACR | chr4 | 166300680 | chr5 | 34006004 | 8 | 18 | GVHEPGVMEK | GCGTCCATGAGCCTGGTGTCATGGAGAAAC |
CPE-AMACR | chr4 | 166300680 | chr5 | 34006004 | 9 | 19 | VHEPGVMEKL | TCCATGAGCCTGGTGTCATGGAGAAACTCC |
![]() |
Fusion gene | Hchr | Hbp | Tchr | Tbp | Start in +/-13AA | End in +/-13AA | FusionNeoAntigen peptide | FusionNEoAntigen RNA sequence |
Top |
Information of the samples that have these potential fusion neoantigens of CPE-AMACR |
![]() |
Cancer type | Fusion gene | Hchr | Hbp | Henst | Tchr | Tbp | Tenst | Sample |
PRAD | CPE-AMACR | chr4 | 166300680 | ENST00000402744 | chr5 | 34006004 | ENST00000335606 | TCGA-KC-A7FD |
Top |
Potential target of CAR-T therapy development for CPE-AMACR |
![]() |
![]() * Minus value of BPloci means that the break point is located before the CDS. |
- In-frame and retained 'Transmembrane'. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
![]() * We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image. |
Hgene | Hchr | Hbp | Henst | Tgene | Tchr | Tbp | Tenst | DeepLoc result |
Top |
Related Drugs to CPE-AMACR |
![]() (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Drug | Source | PMID |
Top |
Related Diseases to CPE-AMACR |
![]() (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
Hgene | Tgene | Disease | Source | PMID |
![]() (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |